- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04831996
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Renal Function and Participants With Renal Impairment
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Florida
-
Hialeah, Florida, United States, 33014
- Clinical Pharmacology of Miami
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants will be classified at screening by renal function based on eGFR as calculated by the MDRD formula and requirement for HD (Group 5).
- Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening.
- Participants eligible for Group 1 should be in good health as determined by no clinically significant deviations from normal for medical history, physical examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at screening or Day -1.
- Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction.
Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.
0Body mass index within the range 18.0 to 40.0 kg/m2 (inclusive) at screening.
- Willingness to avoid pregnancy or fathering children.
- Ability to swallow and retain oral medication.
Exclusion Criteria:
- History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening. Evidence of rapidly deteriorating renal function.
- Participants who have a current, functioning organ transplant or have a scheduled organ transplant within 6 weeks after check-in.
- History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
- History of clinically significant gastrointestinal disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
- Participants eligible for Group 1 who have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1.
- Participants eligible for Groups 2 through 5 who have had a change in disease status within 30 days of screening, as documented by the participant's medical history, deemed clinically significant by the investigator.
- History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study.
- Any major surgery within 4 weeks of screening.
- Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).
- Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1, Day
- 1 (Group 5).
- Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
- Positive test for HBV (HBsAg, HBsAg antibody, and hepatitis B core antibody), HCV (HCV antibody), or HIV. Participants whose results are compatible with prior immunization for HBV may be included at the discretion of the investigator.
Participants eligible for Group 1 who have used tobacco- or nicotine-containing products within 6 months of screening.
- Participants eligible for Groups 2 through 5 who smoke > 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions.
- Positive breath test for ethanol or positive urine or serum screen for drugs of abuse that is not otherwise explained by permitted concomitant medications.
- Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug study.
- Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with strong or moderate inducer or inhibitor of CYP3A4, P-gp,or BCRP.
- For participants eligible for Group 1, use of prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional paracetamol, ibuprofen, and standard-dose vitamins are permitted.
- For participants eligible for Groups 2 through 5, use of prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor.
- Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics. Current clinically significant viral infection at screening or check-in.
- History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
- Inability to undergo venipuncture or tolerate venous access.
- Participants eligible for Group 5 that are not expected to continue HD treatment for the duration of the study.
- Receipt of live (including attenuated) vaccines or anticipation of need for such a vaccine during the study (Note: nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug).
- Known hypersensitivity or severe reaction to parsaclisib or excipients of parsaclisib.
- History of alcoholism within 3 months of screening.
- Women who are pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treat Group 1 : Normal Renal Function
eGFR: ≥ 90 mL/min/1.73 m^2
|
parsaclisib will be administered orally after 8 hours of fasting.
Other Names:
|
Experimental: Treat Group 2 : Mild Renal Impairment
eGFR: 60-89 mL/min/1.73 m^2
|
parsaclisib will be administered orally after 8 hours of fasting.
Other Names:
|
Experimental: Treat Group 3 : Moderate Renal Impairment
eGFR: 30-59 mL/min/1.73 m^2
|
parsaclisib will be administered orally after 8 hours of fasting.
Other Names:
|
Experimental: Treat Group 4 : Severe Renal Impairment
eGFR: 15-29 mL/min/1.73
m^2 and not on Hemo Dialysis
|
parsaclisib will be administered orally after 8 hours of fasting.
Other Names:
|
Experimental: Treat Group 5 : Kidney Failure
eGFR: < 15 mL/min/1.73
m^2 on Hemo Dialysis
|
parsaclisib will be administered orally after 8 hours of fasting.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics Parameter Groups1-4 : Cmax of parsaclisib
Time Frame: 4 Days
|
Maximum Observed Plasma Concentration of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Groups 1-4 : AUC 0-∞ of parsaclisib
Time Frame: 4 Days
|
Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Groups 1-4 : AUC(0-t) of parsaclisib
Time Frame: 4 Days
|
Area Under the concentration- time curve up to the last measurable concentration of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Group 5: Cmax of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Maximum Observed Plasma Concentration of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5 : AUC 0-∞ of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Area Under the Concentration-time Curve From 0 to Infinity of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5: AUC(0-t) of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Area Under the concentration- time curve up to the last measurable concentration of parsaclisib
|
4 Days for period 1 and 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatment Emergent Adverse Events (TEAE) Groups 1-4
Time Frame: up to 11 Days
|
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
|
up to 11 Days
|
Pharmacokinetics Parameter Groups 1-4 : tmax of parsaclisib
Time Frame: 4 Days
|
Time to reach maximum plasma concentration of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Groups 1-4 : t1/2 of parsaclisib
Time Frame: 4 Days
|
Apparent terminal phase disposition half-life of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Groups 1-4 : CL/F of parsaclisib
Time Frame: 4 Days
|
Oral dose clearance of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Groups 1-4 : Vz/F of parsaclisib
Time Frame: 4 Days
|
Apparent oral dose volume of distribution of parsaclisib
|
4 Days
|
Pharmacokinetics Parameter Group 5 : tmax of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Time to reach maximum plasma concentration of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5 : t1/2 of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Apparent terminal phase disposition half-life of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5 : CL/F of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Oral dose clearance of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5 : Vz/F of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Apparent oral dose volume of distribution of parsaclisib
|
4 Days for period 1 and 2
|
Pharmacokinetics Parameter Group 5 during Dialysis - : AUC1-5 of parsaclisib
Time Frame: 4 Days for period 1 and 2
|
Area Under the Concentration-time Curve From 1 to 5 hrs. of parsaclisib
|
4 Days for period 1 and 2
|
Number of Treatment Emergent Adverse Events (TEAE) Group 5
Time Frame: up to 18 Days
|
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
|
up to 18 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCB 50465-109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignancies
-
Amsterdam UMC, location VUmcCompletedColorectum Advanced Malignancies | Breast Advanced Malignancies | Prostate Advanced MalignanciesNetherlands
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnMetastatic Solid Malignancies | Locally Advanced Solid MalignanciesCanada
-
Shandong TheraWisdom Biopharma Co., Ltd.RecruitingAdvanced MalignanciesChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
AstraZenecaParexelCompletedAdvanced MalignanciesUnited Kingdom, United States
-
Innovent Biologics (Suzhou) Co. Ltd.Withdrawn
-
Millennium Pharmaceuticals, Inc.Completed
-
MedImmune LLCCompletedAdvanced MalignanciesUnited States
-
Bristol-Myers SquibbCompletedAdvanced MalignanciesUnited States
-
Symphony Evolution, Inc.Completed
Clinical Trials on parsaclisib
-
Incyte CorporationCompletedAutoimmune Hemolytic AnemiaUnited States, France, Italy, Austria
-
Incyte CorporationActive, not recruitingLymphomaBelgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
-
Incyte CorporationActive, not recruitingLymphomaUnited States, Spain, Italy, Israel, Poland, United Kingdom, Canada, Czechia, Germany, Denmark, Australia, Hungary, Sweden
-
Incyte CorporationCompletedAdvanced MalignanciesUnited States
-
UNC Lineberger Comprehensive Cancer CenterIncyte CorporationWithdrawnBreast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | HER2-positive Breast Cancer
-
Incyte CorporationCompleted
-
Incyte Biosciences Japan GKCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingIndolent Non-hodgkin LymphomaChina
-
Incyte CorporationCompleted
-
Incyte CorporationRecruitingB-Cell MalignanciesUnited States, Spain, Belgium, Japan, Poland, Italy, France, United Kingdom, Israel, Turkey, Norway, Korea, Republic of, Czechia, Sweden, Austria, Hungary, Denmark